Web of Science: 2 cites, Google Scholar: cites
The power and the promise of cell reprogramming : personalized autologous body organ and cell transplantation
Alvarez Palomo, Ana Belen (Universitat de Barcelona. Departament de Ciències Fisiològiques I)
Lucas, Michaela (University of Western Australia. School of Medicine and Pharmacology)
Dilley, Rodney J. (University of Western Australia. School of Surgery)
McLenachan, Samuel (University of Western Australia. Centre for Ophthalmology and Visual Science)
Chen, Fred Kuanfu (University of Western Australia. Centre for Ophthalmology and Visual Science)
Requena, Jordi (Universitat de Barcelona. Departament de Ciències Fisiològiques I)
Sal, Marti Farrera (Universitat de Barcelona. Departament de Ciències Fisiològiques I)
Lucas, Andrew (Murdoch University. Institute for Immunology and Infectious Diseases)
Álvarez, Iñaki (Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí")
Jaraquemada, Dolores (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Edel, Michael J. (Universitat de Barcelona. Departament de Ciències Fisiològiques I)

Data: 2014
Resum: Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) or direct reprogramming to desired cell types are powerful and new in vitro methods for the study of human disease, cell replacement therapy, and drug development. Both methods to reprogram cells are unconstrained by the ethical and social questions raised by embryonic stem cells. iPSC technology promises to enable personalized autologous cell therapy and has the potential to revolutionize cell replacement therapy and regenerative medicine. Potential applications of iPSC technology are rapidly increasing in ambition from discrete cell replacement applications to the iPSC assisted bioengineering of body organs for personalized autologous body organ transplant. Recent work has demonstrated that the generation of organs from iPSCs is a future possibility. The development of embryonic-like organ structures bioengineered from iPSCs has been achieved, such as an early brain structure (cerebral organoids), bone, optic vesicle-like structures (eye), cardiac muscle tissue (heart), primitive pancreas islet cells, a tooth-like structure (teeth), and functional liver buds (liver). Thus, iPSC technology offers, in the future, the powerful and unique possibility to make body organs for transplantation removing the need for organ donation and immune suppressing drugs. Whilst it is clear that iPSCs are rapidly becoming the lead cell type for research into cell replacement therapy and body organ transplantation strategies in humans, it is not known whether (1) such transplants will stimulate host immune responses; and (2) whether this technology will be capable of the bioengineering of a complete and fully functional human organ. This review will not focus on reprogramming to iPSCs, of which a plethora of reviews can be found, but instead focus on the latest developments in direct reprogramming of cells, the bioengineering of body organs from iPSCs, and an analysis of the immune response induced by iPSC-derived cells and tissues.
Nota: Número d'acord de subvenció MICINNO/BFU2011-26596
Nota: Número d'acord de subvenció MICINN/RYC-2010-06512
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l’obra i la creació d’obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l’autoria de l’obra original. Creative Commons
Llengua: Anglès.
Document: article ; recerca ; publishedVersion
Matèria: Direct cell reprogramming ; Ipsc ; Autologous ; Immune response ; Organ bioengineering
Publicat a: Journal of clinical medicine, Vol. 3 (June 2014) , p. 373-387, ISSN 2077-0383

PMID: 26237380
DOI: 10.3390/jcm3020373


15 p, 241.3 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2018-01-29, darrera modificació el 2019-02-07



   Favorit i Compartir